- Summer of 2023 Was Hottest in 2,000 Years
- San Francisco Set to Ban ‘Forever Chemicals’ in Firefighter Gear
- More Studies Support Wegovy’s Long-Term Weight-Loss Benefits
- Americans With Private Insurance May Pay More for Hospital Stay
- Patients Over 80 Still Benefit From Treatment for AML Blood Cancer
- Why C-Section Babies Need 2 Doses of Measles Vaccine
- Vaping Rates Fall Among Teens, But Still Too High
- Science Shows How Night Shifts Help Bring on Disease
- Melanoma Can Strike Black Americans, Often With Deadlier Results
- Smoking During Pregnancy Could Raise Baby’s Odds for Obesity Later
Improved Artificial Heart Valve Approved
The newest version of the Sapien 3 Transcatheter Heart Valve has been approved by the U.S. Food and Drug Administration.
The artificial valve is designed for people with a narrowed aortic valve, a condition that restricts blood flow from the heart to the aorta, the body’s main artery. The product is sanctioned for people who are at high risk for death or serious complications from open-heart surgery to repair the narrowed valve, the FDA said in a news release.
The newly approved device is the third-generation Sapien 3, originally approved in 2011. The newest version includes changes designed to minimize leakage, the FDA said.
In people with aortic stenosis, the heart must work harder to pump blood through the narrowed opening. Symptoms can include fainting, chest pain, heart failure, irregular heartbeat and cardiac arrest.
Possible side effects of the device itself include stroke, serious kidney injury, heart attack, bleeding, the need for a pacemaker or death, the FDA said.
The device isn’t recommended for people who can’t tolerate anti-clotting therapy, the agency said.
The Sapien 3 is manufactured by Edwards Lifesciences, based in Irvine, Calif.
More information
Visit the FDA to learn more.
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.